Assessment of Structural and Functional Pulmonary Vascular Disease in Patients with PAH by Juan Grignola et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Assessment of Structural and  
Functional Pulmonary Vascular  
Disease in Patients with PAH 
Juan Grignola1, Enric Domingo2,3,  
Rio Aguilar-Torres3,4 and Antonio Roman5 
1Dept Pathophysiology, Hospital de Clínicas, Universidad de la República,  
2Area del Cor, Hospital Universitari Vall d’Hebron 
3Dept Physiology, Universitat Autonoma Barcelona 
4Unit of Cardiac Image, Hospital Universitario Bellvitge 
 5Servei de Pneumologia i CIBERES, Hospital Universitari Vall d’Hebron 
1Uruguay 
2,3,4,5Spain 
1. Introduction 
Pulmonary arterial hypertension (PAH) is a life threatening disease characterized by a 
progressive increase in pulmonary blood pressure that often leads to right ventricular (RV) 
failure and death (McLaughlin et al., 2009). A review of the clinical trial data for the three 
classes of drugs approved for the treatment of PAH (prostanoids, endothelin antagonists, and 
phosphodiesterase-5 inhibitors) has shown that all agents have similar efficacy on the 6-min 
walking distance over 12 to 16 weeks, which was the primary endpoint in the randomized 
clinical trials. However, the improvement in the distance walked during the 6-min walking 
test in the patients receiving active therapy that led to drug approval ranged from 3 to 17% 
from baseline. With respect to hemodynamics (which provides direct information about the 
status of the pulmonary circulation) these treatments are unimpressive, producing only a 
minimal reduction in the pulmonary arterial (PA) pressure. Presently, it remains speculative 
how these different drugs act on the pulmonary vasculature of patients with PAH and little is 
known about their long-term efficacy (Rich, 2006). Likewise, recent metaanalysis reported that 
the pooled effect of all treatment strategies shows a significant reduction of 39% (2-62%, 
p=0.041) in all-cause mortality (Galié et al., 2009). The benefits were confined only to patients 
with advanced disease for only 16 weeks, regardless of which class of drug was used. 
However, the mechanism by which mortality decrease remains unknown because it was 
unrelated to a specific class of drug, the dose of the drug, or the effects of the drug on 6-minute 
walking distance or hemodynamics (Macchia et al., 2010). 
The increase in pulmonary arterial pressure in patients with PAH is due to the combination of 
pulmonary vasoconstriction, pulmonary arterial wall remodeling and in situ thrombosis. The 
structural and functional changes in the pulmonary arteries of patients with idiopathic PAH 
(IPAH) (vascular remodeling) include wall thickening of all three layers of the blood vessel 
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wall (adventitia, media and intima) and reduction of the arterial lumen. This is an important 
pathological feature of PAH which leads to increased steady and pulsatile components of the 
pulmonary vascular load. Several studies have shown that the proliferation of PA smooth 
muscle cells in PAH is enhanced, whereas apoptosis is depressed. Among the drugs currently 
used for the treatment of patients with PAH, it was demonstrated that prostacyclin analogues 
inhibit proliferation and promoting apoptosis to a greater extent in distal (< 1 mm external 
diameter) compared with proximal (> 8 mm external diameter) isolated human PA smooth 
muscle cells stimulating the cGMP pathway. These effects were potentiated by sildenafil in an 
independent cAMP pathway mechanism (Wharton et al., 2000, 2005). Recently, it was reported 
that imatinib (a tyrosine kinase inhibitor) also has anti-proliferative and pro-apoptotic effects 
on platelet-derived growth factor-stimulated PA smooth muscle cells from patients with IPAH 
(Nakamura et al., 2011). However, neither of the clinical trials characterize the direct effects of 
the treatments on the vasculature (eg, remodeling), until now. Direct measurement of PA 
structural/functional remodeling with new vascular imaging techniques such as cardiac 
magnetic resonance, intravascular ultrasound (IVUS) or optical coherence tomography (OCT) 
imaging needs to be investigated. Remarkable advances in these techniques provide an 
extraordinary opportunity to gain insight into histopathology that previously could only be 
obtained by open lung biopsy.  
The aim of the present chapter is to evaluate the viscoelastic pulmonary artery properties 
(by IVUS) and PA fibrosis (by OCT) in patients with PAH and its relation to dynamic 
afterload. In addition, we also analyze acute vasoreactivity and its relationship with the 
viscoelastic properties of pulmonary artery vascular wall in patients with IPAH. 
2. Physiological basis of normal local arterial viscoelastic properties 
The viscoelastic properties of the great arteries determine their main functions: to conduct 
blood (conduction function) and to buffer the pulse pressure and flow generated by 
ventricular ejection (wall buffering function). In general, the elastic and viscous properties of 
the arterial wall have been characterized together as “viscoelasticity.” Various studies have 
demonstrated that the elasticity and viscosity of the arterial wall play different roles in 
arterial function, and can also be independently affected by physiologic, pathologic or 
experimental conditions (Nichols & O’Rourke, 2005).  
Elasticity depends strongly on pressure and therefore increases significantly during 
increased arterial pressure. Elastin, collagen, and vascular smooth muscle have different 
elastic moduli. They all start to stretch at different levels of arterial wall strain, thus the ratio 
of pressure to diameter is non-linear. At higher pressure, the recruitment of more rigid 
collagen fibers is greater, and elasticity increases. The degree of activation of vascular 
smooth muscle also affected arterial elasticity. Elastin and collagen keep the level of arterial 
stress stable, which allows cyclic elastic arterial stretching and recovery but prevents over-
distension and arterial wall disruption. In contrast, vascular smooth muscle is a dynamic 
component whose elasticity depends not only on the distension pressure but also on its 
extent of activation. The elastic response of the artery is an important determinant of its 
conduction and buffering functions. An adequate elastic modulus allows systolic distension 
of the artery and the subsequent diastolic elastic recoil, which ensures the continuous 
anterograde blood flow. In addition, an adequate elastic modulus reduces the oscillations 
generated by the heart, ensuring a high mean arterial pressure and a low pulsatility. 
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Previous studies performed in systemic arteries and the PA showed that activation of 
vascular smooth muscle increases arterial wall elasticity as a function of deformation or 
diameter (isometric analysis), or decreases arterial stiffness as a function of strain or 
pressure (isobaric analysis). Our experimental data agree with these studies because 
elasticity, when measured at constant pressure, decreased with muscular activation (passive 
versus active PH) (Bia et al., 2005a).  
Arterial wall viscosity has been associated mainly with energy loss during the cardiac cycle and 
might be directly associated with the amount and degree of activation of vascular smooth 
muscle. We have demonstrated that only the activation of vascular smooth muscle increased 
viscosity with respect to the control value in both PA and aorta. Moreover, viscosity was greater 
in the aorta than in the PA during control and hypertensive states (Bia et al., 2003). The viscosity 
of arterial tissue might be explained by one of two theories (Nichols & O’Rourke, 2005). The 
«passive» theory assumes that viscosity is a property of the constituents of the arterial wall 
(being vascular smooth muscle the most important). The «active» theory considers the 
mechanisms generating muscle contraction (activation) and myogenic response to stretching to 
be important. The viscous response of the arterial wall is independent of pressure and 
attenuates the highest frequency components of the incident waves of pressure and flow and 
the amplitude of the reflected waves that could trigger resonance phenomena in the system. A 
higher viscosity denotes a greater energy cost during the pulsatile expansion of the vessel in 
each cardiac cycle and is associated with a higher buffering function (Bia et al., 2005b). 
Arterial wall buffering function could be defined by arterial wall viscosity/elasticity ratio. The 
arterial elasticity is highly dependent on blood pressure, and the viscosity values related to 
the amount of vascular smooth muscle and its degree of activation. Recently, in anesthetized 
animals, Bia et al found that the local wall buffering function of the ascending aorta and the 
main PA is similar despite their differences in elastic and viscous response. In both arteries, 
during active hypertension, the wall buffering function remained similar to the basal value, 
despite the increased pressure dependent upon the elastic modulus. This maintenance of the 
wall buffering function is due to the increase in the viscous modulus generated by the 
muscle activation (Bia et al., 2003). 
3. Intravascular ultrasound (IVUS): A functional approach for the evaluation 
of pulmonary arterial wall viscoelasticity in PAH 
In the clinical setting, the hemodynamic characterization of the pulmonary vascular tree and 
the response to vasoactive drugs is achieved by applying Poiseuille’s law from pressure and 
cardiac output determinations during right heart catheterisation. However, these 
measurements have several limitations: a) they only assess the status of the stationary 
component of the pulmonary vasculature, neglecting the essentials of a pulsatile circulation; 
b) they correlate weakly with histological findings; and c) they do not have the ability to 
evaluate both structural and functional states of the PA wall (Saouti et al., 2010).   
Resistance is only one component of afterload, and its calculations assume a constant blood 
flow, whereas compliance, capacitance and impedance are more useful to describe pulsatile 
flow. The PA stiffness assessment better reflects these latter components that could 
contribute to worsening right heart failure. Several studies have begun to measure and 
explore the clinical relevance of PA stiffness in PH.  
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PA stiffness is an important factor governing dynamic afterload. It has also been reported that 
proximal PA stiffness may increase early in the course of PH, suggesting a potential 
contributory role of PA stiffness in the development and progression of PH. The association 
between vascular stiffening and disease severity is believed to be due to several factors: a) 
stiffening reduces the windkessel effect of the elastic arteries, leading to greater flow 
inefficiency; b) stiffening increases RV afterload independent of pulmonary vascular resistance 
(PVR); and c) changes in the flow and pressure waveforms due to stiffening of the pulmonary 
circulation have been shown to stimulate cellular signaling pathways in distal vessels and the 
lungs that aggravate the existent vascular disease. Increased stiffness observed in PA 
hypertension may be secondary to elevated distending pressures or/and to structural changes 
of the PA wall. IVUS has been used for quantifying the pulsatility of PA (IVUSp) in IPAH 
(Berger et al., 2002; Rodés-Cabau et al., 2003). The arterial pulsatility depends on intraluminal 
pressure and on viscoelastic properties of the arterial wall, while stiffness depends on the 
extent of wall remodeling. The lack of correlation between IVUSp and usual hemodynamic 
variables in patients with IPAH suggests that wall remodeling may influence the functional 
properties of the arterial wall derived from IVUS. We have already experimentally 
demonstrated that only those indexes of wall stiffness that simultaneously consider changes of 
pressure and diameter of PA are correlated with the incremental elastic modulus (gold 
standard for the elastic properties of a vessel wall) (Bia et al., 2005a). It has been reported that a 
decreased pulsatility of both proximal (magnetic resonance imaging) (Gan et al., 2007; Sanz, 
Fernández-Friera & Moral, 2010) and distal (IVUS) (Rodés-Cabau et al., 2003) PA is related to 
increased long term mortality in patients with IPAH. However, because of the strong 
dependency of strain on underlying pressures, quantification of IVUSp alone is insufficient to 
fully characterize PA elastic properties, explaining the absence of its correlation with basic 
hemodynamic parameters (Rodés-Cabau et al., 2003; Grignola et al., 2010).  
3.1 Estimation of local pulmonary arterial pulsatility and stiffness indexes by IVUS 
We studied twenty five consecutive patients with IPAH who underwent cardiac 
catheterisation. Hemodynamic evaluation and IVUS imaging of the PA were performed 
during the same procedure according to a protocol previously reported. All patients 
underwent a routine right heart catheterisation and simultaneous IVUS in a supine position 
and breathing room air (Rodés-Cabau et al., 2003). A 7F Swan-Ganz catheter (Edwards 
Lifesciences, USA) was inserted into a brachial vein and a 5F end-hole catheter was inserted 
into the right radial artery to monitor systemic arterial pressure. Both catheters were 
connected to fluid-filled transducers which were positioned at the anterior axillary line level 
and zeroed at the atmospheric pressure. Right atrial pressure, PA pressure, pulmonary 
arterial occlusion pressure (PAOP) and systemic arterial pressure were measured. Cardiac 
output was estimated by the Fick method assuming basal oxygen consumption  
(125 ml O2/min/m2) (Soto & Kleczka, 2008). Cardiac index was calculated by dividing the 
cardiac output by body surface area. After hemodynamic measurements were done, an 
Eagle Eye Gold catheter 20MHz, 3.5F (Volcano Corporation, USA) with an axial resolution 
of 200m and a pullback of 0.5mm/s, was advanced over a 0.014” guidewire into the same 
PA branch using an exchange guidewire system and X-ray control (Fig. 1). This method 
guarantees that IVUS images and PA pressure are obtained from the same arterial segment 
in the pulmonary arterial tree. The images were obtained from the segmental PA of the 
inferior lobes (elastic PA between 2-4 mm) (Bressollette et al., 2001) and stored in digital 
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format. The images were independently analyzed off-line by two observers blinded for 
clinical and hemodynamic findings (E.D., M.V.). The end-diastolic (minimal) and end-
systolic (maximal) cross-sectional areas of the distal segment were measured (Fig. 2). 
Pulmonary vascular disease is diffuse but not uniform in the pulmonary tree. However, 
considering that Bresollette et al. have shown that structural abnormalities were 
significantly more severe in the lower lobes, it is possible that the pulmonary vascular 
disease process associated with PH begins in this region because of the higher hydrostatic 
pressure (Bresollette et al., 2001). 
Steady (PVR) and pulsatile (pulmonary arterial capacitance, Cp) components of afterload 
were estimated. PVR and Cp were calculated as (mean PA pressure-PAOP)/cardiac output 
and the ratio between the stroke volume and the PA pulse pressure (SV/Pp), respectively. 
IVUSp was estimated as: ((systolic area-diastolic area)/diastolic area)) 100; ((sA-dA)/dA)  
100 (Fig. 2). 
PA stiffness indexes were assessed by arterial cross-sectional area and local Pp (Rodés-
Cabau et al., 2003; Laurent et al., 2007; Grignola et al., 2010): 
 Elastic modulus (EP): dA  Pp /(sA-dA)                            (1) 
 Cross-sectional distensibility (DCS): IVUSp  Pp                           (2) 
 Local compliance (CL): (sA - dA) / Pp                              (3) 
 
 
Fig. 1. Eagle Eye Gold imaging catheter (20 MHz) and console (Volcano Corporation). 
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Fig. 2. Representative IVUS images of a patient with IPAH. Left side: systolic phase and 
right side: diastolic phase of the cardiac cycle. (IVUSp = 11.8-9.4/9.4 = 25.5%). 
Figure 3 shows mean values of IVUSp and EP in four groups of patients studied at our 
institution: ten control patients (with suspicion of PAH); a recent group of eighteen IPAH 
patients (2008-2009) split into two groups according to the median of EP (group 1 ≤ 190 
mmHg and group 2 > 190 mmHg) and a historical group of more severe IPAH patients 
(prior to 2003) (Rodés-Cabau et al., 2003; Domingo et al., 2011). 
It can be seen that control group patients have a significantly lower EP and higher IVUSp than 
IPAH patients. In according with our results, Berger et al. showed that arterial wall 
distensibility (the inverse of EP) significantly decreased in children with advanced pulmonary 
vascular disease in comparison with normal subjects, corresponding with an average EP of 182 
mmHg versus 50 mmHg (Berger et al., 2001). However, they did not find differences in 
vascular pulsatility between patients with pulmonary vascular disease and control subjects. 
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Fig. 3. Bar diagram showing the mean ± ES of elastic modulus and pulsatility (IVUSp) 
of control (n=10) and IPAH patients (Group 1, n=9; Group 2, n=10 and Rodés-Cabau,  
n=20). 
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We suggest that IVUSp and EP are different qualitative indexes of the arterial wall 
viscoelastic properties. IVUSp is a normalized cross-sectional pulsatility that depends only 
on arterial cross-sectional signals (geometric related index) and EP is a local PA stiffness 
index normalized by Pp.  
We have previously shown that PA arterial wall indexes that depend only on arterial 
geometric signals (such as normalized cross-sectional pulsatility) do not follow the same 
patterns as the incremental elastic modulus (EINC, gold standard of the elastic properties of a 
vessel wall) (Bia et al., 2005a). Only during vascular smooth muscle activation did arterial 
cross-sectional area and wall viscosity increase with regard to the passive situation and 
independent from the pulse pressure level, suggesting that absolute or normalized pulse 
cross-sectional area could be an indirect or qualitative marker of arterial wall viscosity 
status. In relation to this, the absence of a relation between IVUSp and hemodynamic 
variables suggests that changes in pulmonary vessel structure are responsible for functional 
alteration shown by ultrasound (Rodés-Cabau et al., 2003). 
The incremental elastic modulus is commonly used in elasticity theory because it best 
defines the intrinsic properties (independently of size or geometry) of a given material (eg, 
the arterial wall). Consequently, it is considered the “gold standard” for the evaluation of 
the elastic response of a material. The requirement for the geometric characteristics of the 
arterial segment (thickness and diameter of the arterial wall) to be known makes this a 
difficult modulus to calculate in a clinical setting. The EP allows calculation of the arterial 
rigidity in relation to the unit strain, and as such, is independent of the diameter or cross-
sectional area. Its particular clinical usefulness comes from the fact that it is only necessary 
to know the maximum systolic and minimum diastolic values of the arterial pressure and 
cross-sectional signals in order to perform the calculation. However, since the calculation 
requires the use of the maximum and minimum values for pressure and cross-sectional in 
order to calculate the secant between these points, its values include both the elastic and 
viscous behavior of the arterial wall. Thus, due to the viscoelastic characteristic of the 
arterial wall, the maximum systolic diameter of the artery reached during arterial distension 
is highly dependent upon the level of arterial viscosity (Bia et al., 2005b). 
Therefore, we can state that IVUSp is very dependent on wall viscosity and that EP depends 
on the mechanical effect of PA pressure, the vascular smooth muscle tone variations, and the 
changes in the PA wall structure. So, as might be expected, control patients have the higher 
wall PA buffering function (higher IVUSp plus the lower EP), and the group studied by 
Rodés-Cabau showed the worst PA buffering function (Fig. 3).  
3.2 Correlation of local pulmonary arterial stiffness indexes with steady and pulsatile 
afterload 
The arterial hydraulic load can be described completely by the so-called pulmonary arterial 
input impedance that accounts for the relationship between pulsatile pressure and flow. 
However, this description is not only difficult to derive but also complex to interpret 
(Nichols & O’Rourke, 2005). Therefore, several simplified descriptions of the arterial 
circulation have been proposed. One such description is the two-element Windkessel model 
which consists of physiologically easily interpretable parameters and describes the 
hemodynamics in terms of resistance and compliance. The resistance of the model is the 
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PVR. PVR is mainly located in the small arteries and arterioles, since resistance strongly 
depends on vessel diameter. The compliance of the model (Cp) is the storage capacity of all 
arteries and arterioles taken together. Cp is related to arterial wall elasticity and vessel size 
(i.e. radius and wall thickness). The compliance of the arterial tree allows the arteries to 
expand passively during systole and to recoil during diastole. This has two important 
effects: a) the compliant arteries are able to store the ejected blood-volume in systole and 
release this volume during diastole resulting in constant peripheral blood flow throughout 
the entire cardiac cycle and, b) the compliant arteries dampen/cushion the pressure so that 
pressure variations in the PA are smaller than in the ventricle. If we assume that the 
periphery is closed for a moment, the increase in pressure (∆P = Pp) resulting from a single 
stroke volume (SV) relates thus to compliance: Cp = SV/Pp, which overestimates the real 
compliance. Calculation of Cp is, in practice, more difficult because there is blood leaving 
the arterial system through the periphery (microcirculation) while cardiac ejection takes 
place. Although the pulse pressure method was shown to result in reliable data, the SV/Pp 
ratio is an acceptable method to derive compliance in vivo (Chemla et al., 1998; Stergiopulos, 
Segers & Westerhof, 1999).  
Clinicians usually define RV afterload in terms of PVR and this measure is often used as a 
primary or secondary end-point in clinical studies. However, PVR only reflects the non-
pulsatile (steady) component of blood flow, and neglects the important contribution of 
compliance. In recent years it has become clear that in PH not only the contribution of PVR 
is of importance but that the decrease in Cp plays an equally important role. Cp takes into 
account the pulsatile components of the arterial load and, therefore, is an important factor 
contributing to systolic and diastolic pressure. Besides, it was shown to be a prognosis factor 
for mortality (Mahapatra et al., 2006). It is noteworthy that the common PA and proximal 
left and right arteries together contribute only 15-20% of total Cp, suggesting that arterial 
compliance is distributed over the entire pulmonary arterial bed, like PVR (Saouti et al., 
2010). On the contrary, in the systemic arterial tree the compliance is mainly located in the 
aorta (80% of total compliance in thoracic-abdominal aorta), and resistance is mainly located 
in arterioles. This distribution depends on the number of peripheral vessels, which is ≈ 8-10 
times more in the pulmonary system than in the systemic tree (Saouti et al., 2010). 
Cp quantifies total (rather than local) arterial compliance, given an average of what is 
happening in the whole arterial pulmonary tree without allowing the analysis of regional 
changes and to detect early-stage wall remodeling. As we previously mentioned, the 
simultaneous use of IVUS and conventional RHC allowed us to estimate local viscoelastic 
properties of the PA as a whole. A major advantage is that local arterial stiffness is directly 
determined from the change in pressure driving the change in volume, i.e. without using 
any model of the circulation. Both the change in pressure and size should be obtained from 
the same arterial segment. It has also been reported that proximal PA stiffness may increase 
early in the course of IPAH, suggesting a potential contributory role of PA stiffness in the 
development and progression of PAH (Sanz et al., 2009).  
In spite of IPAH patients with higher wall stiffness (group 2 and Rodés-Cabau group) 
showing lower IVUSp are associated with decreased Cp and increased PVR, neither Cp nor 
PVR correlated with IVUSp (Fig. 4). On the contrary, the three local PA stiffness indexes 
(normalized by pulse pressure) correlated significantly with global capacitance and 
resistance properties of the pulmonary arterial tree (Fig. 5) (Grignola et al., 2010). 
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As mentioned before, the assessment of PA stiffness indexes requires the use of the 
maximum and minimum values for pressure and cross-sectional area including both the 
elastic and viscous behavior of the PA arterial wall. 
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Fig. 4. Absence of correlation between pulsatility (IVUSp) and pulsatile (Cp, capacitance 
index) and steady (PVR, pulmonary vascular resistance) pulmonary afterload components. 
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Fig. 5. Correlations between local PA stiffness indexes normalized by pulse pressure and 
pulsatile (Cp, capacitance index) and steady (PVR, pulmonary vascular resistance) 
pulmonary afterload (n=25). 
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By contrast, IVUSp is only an indirect marker of arterial wall viscosity status, explaining the 
absence of correlation between IVUSp and afterload parameters. 
Recent studies showed that PVR and Cp are inversely related by a hyperbola, and  
in combination describe the RV afterload better than either PVR or Cp separately 
(Lankhaar et al., 2006, 2008). In other words, the product i.e. the RC-time, in the 
pulmonary circulation remains the same in healthy subjects and in patients with IPAH 
and chronic thromboembolic pulmonary hypertension, and even after treatment (Saouti et 
al., 2010). 
Figure 6 shows that in the early stage of PAH a small increase in PVR will be accompanied 
by a relatively large drop in Cp (patient A). However, in later stages when the vascular 
disease progresses, the increase in PVR will continue but the drop in Cp will be limited as 
the vascular wall stiffness will reach a maximum (patient B).  
 
 
Fig. 6. Inverse hyperbolic relationship between pulmonary arterial compliance (Cp) and 
pulmonary vascular resistance (PVR). ∆: change. 
Finally, compliance in the pulmonary arterial system is distributed over the entire arterial 
system and stands at the basis of the constancy of the RC time. Applying this RC approach, 
we can see that patients with an EP lower than the median (group 1, EP < 190 mmHg) are 
distributed in the upper left of the hyperbola and that patients of group 2 (EP ≥ 190 mmHg) 
hold the bottom right of the RC curve (Fig. 7A). On the contrary, splitting the patients 
according to the median of the IVUSp (23%) does not reveal any specific distribution along 
the RC curve (Fig. 7B). We can affirm that patients with lesser changes in pulmonary 
vascular bed (EP < 190 mmHg) are characterized by the fact that a small change of PVR leads 
to a considerable change in Cp and can, therefore, be better detected by a change in 
compliance than a change in PVR and viceversa. 
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Fig. 7. RC curve of patients with IPAH.  The population was split into two groups according 
to the median of EP and IVUSp. 
3.3 Correlation of local pulmonary arterial elastic modulus with acute vasoreactivity 
Detection of acute pulmonary vasoreactivity is important for the evaluation of patients with 
PAH in different scenarios (Tonelli, Alnuaimat & Mubarak, 2010). However, the clinical 
relevance of acute vasoreactivity testing in PAH for identifying patients with a marked 
vasoreactive component, who may thus benefit from chronic calcium channel blocker 
therapy, has been established only in IPAH (Ghofrani, Wilkins & Rich, 2008). The criteria for 
identifying responder and non-responder patients in IPAH have been changed in the last 
twenty years (Tonelli, Alnuamat & Mubarak, 2010). Nowadays, according to the 
retrospective study of Sitbon et al., a positive response is defined as a decrease in mean PA 
pressure (Pm) > 10 mmHg, reaching an absolute Pm < 40 mmHg with an unchanged or 
increased cardiac output (Sitbon et al., 2005). However, the acute response to a vasodilator 
agent is not an all-or-nothing phenomenon, since different degrees of vasoreactivity are 
present in all patients with PAH, even in those defined as non-responders by the revised 
current criteria (Vieira Costa et al., 2005). Pathophysiologically, the different criteria used 
throughout time to define a positive response may identify patients with different degrees 
of vascular remodeling. It has been suggested that the currently used criteria of acute 
responder might identify those patients with a predominant vasoconstriction, a better 
hemodynamic profile and less remodeling of the vascular wall (Vieira Costa et al., 2005). 
Recently, Jardim et al. have proposed PA distensibility ≥ 10% (magnetic resonance imaging) 
as a noninvasive surrogate response marker to the acute vasodilator test in patients with 
PAH (Jardim et al., 2007). 
However, one aspect that has not been evaluated to date is the relationship between 
pulmonary arterial wall stiffness, real absolute vasodilatation, and vasoreactivity response 
(in terms of conventional vasoreactivity criteria) during the acute vasoreactivity testing. 
Hemodynamic evaluation and IVUS imaging of the PA were performed in the same 
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procedure according to a protocol previously reported (Rodés-Cabau et al., 2003; Grignola et 
al., 2011). Table 1 describes the baseline clinical and hemodynamic characteristics of the 19 
IPAH patients enrolled in the study.  
 
 
Variables Value 
Demographic variables  
Age, years 52  15 
Gender, M / F 6 / 13 
Functional status  
NYHA class I-II / III-IV 12 / 7 
6MWD, m 386  105 
Hemodynamic measurements  
CI, l/m/m2 2.4  0.8 
SVI ml/m2 30  10 
Pm, mmHg 47  18 
Pp, mmHg 47  20 
RAP, mmHg 8.2  4.8 
PVRi, WU.m2 21  12 
PAOP, mmHg 10  3 
SvO2, % 64  7 
Table 1. Clinical and hemodynamic data of the patients with IPAH (n=19). (CI: cardiac 
index; PAOP: pulmonary arterial occlusion pressure; Pm and Pp: mean and pulse arterial 
pulmonary pressures; PVRi: pulmonary vascular resistance index; RAP: mean right atrial 
pressure; SVI: stroke volume index; SvO2: mixed venous oxygen saturation; 6MWD: six-
minute walking distance). 
Acute vasoreactivity testing was performed after baseline measurements, using intravenous 
epoprostenol. The infusion of epoprostenol was started at a dose of 2 ng/kg/min, and 
increased progressively (2 ng/kg/min every 10 to 15 min) until a positive response was 
obtained or until side effects occurred (Grignola et al., 2011). Both the pressure and cross-
sectional area changes of PA were obtained during two stable hemodynamic states: baseline 
and epoprostenol infusion. The population was split into two groups according to the 
presence of real absolute vasodilatation (delta dA ≥ 10%) (Jardim et al, 2007). The mean dose 
of epoprostenol was similar in both groups (11  2 ng/kg/min in the vasodilator group and 
10  1.2 ng/kg/min in the non-vasodilator group) (Table 2). 
Both groups showed a significant heart rate increase and mean aortic pressure decrease 
(p<0.05). PAOP did not change during epoprostenol infusion. Among patients who showed 
a real vasodilatation (delta dA ≥ 10%), 5 of the 6 had an elastic modulus below the median 
value (190 mmHg), and presented baseline lower elastic modulus and higher IVUSp. On the 
other hand, among the patients who did not present a vasodilatation, 9 of 13 had an elastic 
modulus above the median value. A ROC curve showed that the presence of PA stiffness 
below the median value was able to differentiate patients with an acute vasodilator 
response, with 83% sensitivity (95% confidence interval of 54-113%) and 70% specificity 
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(95% confidence interval of 44-94%). The area under the ROC curve was found to be 0.81 
(95% confidence interval 0.58-1.04; p<0.05). We choose this cut-off value for EP since it 
corresponds to the maximum Youden’s index (J=0.53). However, no significant relationship 
has been found between baseline PA wall stiffness and vasodilator response and the 
decrease in Pm and/or in PVRi during acute vasoreactivity testing. 
 
 
 
All patients             
(n=19) 
Vasodilator group (n=6)
Non-vasodilator group  
(n=13) 
 Basal Epo Basal Epo Basal Epo 
CI, l/m/m2 2.3  0,6 2.7  1.3† 2.7  1.0 3.3  1.2† 2.3  0.6‡ 2.5  0.9 
SVI ml/m2 30  10 33  15 30  14 42  16† 30  8‡ 28  7 
Pm, mmHg 50  18 47  18 49  17 48  20 46  16 42  14 
Pp, mmHg 50  20 31  12† 50  18 46  20 44  16 41  16 
PVRi, Wu.m2 21  12 15  9† 24  17 17  11† 19  10 15  7 
Cp, ml/mmHg 1.38  1 2.1  1.1† 1.4  0.9 1.8  1.2† 1.3  0.8 1.4  0.7 
IVUSp, % 27.8  12.9 23.8  10.5† 35.6  17 26.5  15† 24.0  8.4‡ 22.1  6.5 
EP, mmHg 195  97 220  124 173  85 244  110 224  81 206  87 
dArea, mm2 11.7  7.6 10.3  7.2 11.3  10.8 12.4  11.6 12.0  6.0 9.1  2.6 
sArea, mm2 15.1  10 12.7  9 15.2  14.5 15.5  14.5 15.0  8.0 11.0  3.4 
ΔArea, mm2 3.3  2.7 2.3  2.1† 4.0  3.9 3.3  3.3 3.0  2.1 1.9  1.1 
Table 2. Hemodynamic and IVUS data before (baseline) and after acute vasoreactivity 
testing (Epo) of both groups. (CI: cardiac index; Cp: pulmonary capacitance index; dArea 
and sArea: diastolic and systolic lumen area; EP: elastic modulus; IVUSp: pulmonary arterial 
pulsatility; Pm and Pp: mean and pulse arterial pulmonary pressures; PVRi: pulmonary 
vascular resistance index; SVI: stroke volume index. †p<0.05 Basal vs. Epo; ‡p<0.05 between 
basal conditions of two groups). 
The similar baseline Pm and Pp between both groups allows to state that the acute real 
vasodilator response is the direct consequence of better preserved viscoelastic wall 
properties of PAs. No significant relationship has been found between PA wall stiffness and 
vasodilator response and the decrease in Pm and/or in PVRi during acute vasoreactivity 
testing. This is not consistent with the hypothesis that a favorable vasoreactive response is 
related to a less advanced stage of the pulmonary vascular disease (Raffy et al., 1996). 
Therefore, the acute vasodilatation responder patient may not always be the acute 
vasoreactive responder patient (current criteria). 
The analysis of IVUSp and EP during the acute vasoreactivity testing showed that the 
patients with a vasodilator response had an isobaric (similar Pm) worsening of IVUSp 
(p<0.05) and of EP (p=0.08). This is in agreement with Cholley et al. who reported that the 
isobaric relaxation of vascular wall smooth muscle produces a paradoxical increase in 
aortic stiffness with a concomitant increase in the incremental elastic modulus (Cholley et 
al., 2001). In other words, PA vasodilation by itself may cause the vessel to become stiffer 
since it is operating at a higher internal diameter. This fact would cause a redistribution of 
parietal stress into the different components of the PA wall, recruiting collagen fibers with 
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higher stiffness, lower viscosity and lower wall buffering function, producing 
deterioration of IVUSp and EP. This paradoxical response may also explain the lack of 
correlation between baseline EP and hemodynamic vasoreactivity during epoprostenol 
infusion.  
In our cohort, the patients who showed a real absolute pulmonary artery vasodilation 
during acute vasoreactivity testing, had an isobaric response (absence of changes in Pm) 
with a concomitant stroke volume index increase (40%), Cp increase (29%) and PVRi 
decrease (30%). The patients with a positive vasoreactive response according to current 
criteria do not necessarily have a real absolute vasodilatation on IVUS (Grignola et al., 
2011). As proposed by Raffy et al., acute positive vasoreactive response to epoprostenol 
could be used identify a particular subgroup in the IPAH population that is characterized 
by a spontaneously slower evolution and hence a better prognosis (Raffy et al., 1996). The 
absence of IVUSp and EP worsening during short-term response to epoprostenol in the 
non-vasodilator and higher remodeling group of IPAH patients could support the greater 
benefit of epoprostenol in patients with worse functional class. Future studies should 
analyse whether absolute vasodilatation during acute vasodilator challenge is the most 
useful criterion to determine responders to calcium channel blocking therapy. We firmly 
believe that the study of local stiffness indexes of distal PA in IPAH may be useful for 
analyzing direct and long term effects of specific drugs designed for IPAH treatment on 
the remodeling process of the pulmonary arterial vascular tree (Rich, 2009; Rich et al., 
2010). 
4. Optical Coherence Tomography (OCT): A structural approach for the 
evaluation of pulmonary arterial wall in PAH 
Optical Coherence Tomography (OCT) has emerged in recent years as one of the most 
promising intravascular imaging modalities, capable of providing cross-sectional images of 
tissue with a homoaxial resolution of 10 µm and a lateral resolution of 20 µm, which is ≈ 10 
times higher than that of any available imaging modality (Table 3).  
The principle of OCT is analogous to pulse-echo ultrasound imaging: however, light is 
used rather than sound to create the image. Whereas US produces images from the 
backscattered sound “echoes”, OCT uses infrared light waves that reflected off the 
internal microstructure within the biological tissues due to their differing optical indices. 
The use of light provides significantly higher spatial resolution than that of any 
ultrasound technique. However, this is at the expense of a reduced penetration depth and 
the need to create a blood-free environment for imaging. In small arteries (diameter lesser 
than 2-3 mm), blood (namely red blood cells) represents a non-transparent tissue causing 
multiple scattering and substantial signal attenuation. As a consequence, blood must be 
displaced during OCT imaging, with the need for balloon occlusion and intra-arterial 
flush (Pratty et al., 2010).  
OCT utilizes a near-infrared light emitted by a super-luminescent diode in combination with 
advanced fibre-optics to create a dataset of the artery studied. Both the bandwidth of the 
infrared light used and the wave velocity are orders of magnitude higher than in medical 
ultrasound. The resulting resolution depends primarily on the ratio of these parameters, and 
is one order of magnitude larger than that of IVUS (Table 3).  
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 TD-OCT IVUS 
Energy source Near-infrared light Ultrasound (20-45 MHz) 
Wave-length, µm  1.3 35 - 80 
Resolution, µ 15-20 (axial); 20-40 (lateral) 100-200 (axial); 200-300 (lateral) 
Probe size (µ) 400 1100 
Frame rate, frames/s 15-20 30 
Tissue penetration, mm 1-2.5 10 
Pull-back rate, mm/s 1-3 0.5-1, up to 40 
Max scan diameter, mm 7 15 
Table 3. Physical characteristics of time-domain optical coherence tomography vs. IVUS. 
Analogous to ultrasound imaging, the echo time delay of the emitted light is used to 
generate spatial image information and the intensity of the received (reflected or scattered) 
light is translated into a (false) colour scale. As the speed of light is much faster than that of 
sound, an interferometer is required to measure the backscattered light (Regar et al., 2003; 
Farooq et al., 2009; Pratty et al., 2010). OCT produces accurate images of the arterial lumen 
and the lumen-vessel wall interface. Normal arteries show a clear demarcation between 
tunica intima (highly reflective), tunica media (poorly reflective) and tunica adventitia 
(highly reflective) by OCT (Regar et al., 2003) (Fig. 8). Lipid and necrotic tissue are 
visualized as poorly reflective structures, while fibrous tissue shows a highly reflective, 
uniform pattern within the artery wall. 
 
 
  
 
 
 
 
 
 
 
 
Fig. 8. Left and middle: in vivo OCT image of a normal artery with the different layers.  
Right: Time-Domain OCT system (Lightlab Imaging, Westford, MA, USA). 
 Intima     Media    Adventitia
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Second-generation OCT systems have now been developed that potentially overcome many 
of the practical limitations of the TD-OCT scanners. This technology utilizes a detection 
method termed Fourier or frequency-domain detection, which allows high-speed data 
acquisition and real-time imaging. Using guide catheter flush without balloon occlusion, 
imaging at ≥ 100 frames per second with a pull-back rate of up to 20 mm/second has been 
achieved, in contrast to 5.6 frames/second for the TD-OCT system. This development has 
led to faster image acquisition speeds, with greater penetration depth and without loss of 
vital detail or resolution, and represents a great advance on current conventional OCT 
systems (Raffel et al., 2008; Gonzalo et al., 2010).  
4.1 Estimation of local pulmonary fibrosis by OCT 
Although the focus in understanding the mechanism of PAH has been on the small PA (< 
500 μ), there is evidence that changes in impedance, resulting from stiffening of the more 
proximal conduit PAs, may also be a critical determinant not only of the pressure but of the 
ability of the right ventricle to function (Rabinovitch, 2008). 
In Heath and Edwards’ histopathological classification, structural changes in the PAs 
include the progressive intimal fibrosis from the smaller muscular PA to the medium-sized 
PA (Heath & Edwards, 1958). In spite of similar clinical and hemodynamic profiles, patients 
differed considerably with respect to the nature of their pulmonary vascular obstructive 
lesions. Palevsky et al showed that an intimal area of more than 18% of the vascular cross-
sectional area had an 85% predictive value for identifying patients with a poor outcome 
during 36 months of follow-up (Palevsky et al., 1989). Therefore, accurate detection and 
quantification of intimal fibrosis would be important in the assessment of PA remodeling, 
irreversibility and prognosis of the disease. Besides, it has recently been shown that collagen 
content is important in extralobar PA stiffening caused by chronic hypoxia (Ooi et al., 2010). 
Finally, there is evidence that conduit PA stiffness is a strong predictor of mortality in PAH 
(Mahapatra et al., 2006; Gan et al., 2007).  
According to our knowledge, there is scarce and poorly analyzed literature on the use of 
OCT in PAH. Tatebe et al reported the potential usefulness of OCT as a novel diagnostic tool 
for the differential diagnosis of distal type chronic thromboembolic PH from PAH (Tatebe et 
al., 2010). They showed that PA > 1 mm in diameter had no obstruction in the control of 
PAH subjects, although the media of the arteries appeared to be thickened in PAH subjects 
compared with controls. Finally, Hou et al. reported the OCT findings of one case of severe 
IPAH (Hou et al., 2010). They showed that the intima was more than twice the thickness in 
this patient with PH compared with a patient with normal PA pressure. 
We quantified the relative PA wall fibrosis (%Fib) by OCT in patients with stable IPAH 
(Domingo et al., 2010). After hemodynamic and IVUS measurements, a Helios coaxial 
occlusion balloon catheter (LightLab Imaging Inc, Westford MA, USA) was advanced over a 
0,014” guidewire into the same pulmonary artery branch, using an exchange guidewire 
system and X-ray control. This method guarantees that IVUS, OCT and PA pressure are 
obtained at the same level of the studied PA branch. The Helios is situated in the distal part 
of the vessel. The guidewire is replaced by an ImageWire 2000 OCT imaging catheter 
(LightLab Imaging Inc, Westford MA, USA). While maintaining the ImageWire in its place, 
the balloon is retracted to the proximal part of the branch. To prevent blood from entering 
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the region of interest, the balloon is inflated to 0.6 atm. Total occlusion is verified 
angiographically with a contrast injection. When occlusion is achieved, a manual continuous 
flush with saline is initiated for blood clearing. According to the study from Yabushita et al., 
fibrosis is represented by OCT as intimal thickening with a bright and homogeneous signal 
(Yabushita et al., 2002). In the same image the inner lumen area and the area limited by the 
outer boundary of fibrosis are measured. Subtraction of these two areas represents fibrosis 
area. Percentage of fibrosis is calculated as the ratio between the fibrosis/lumen cross-
sectional areas (%Fib): 
 %Fib = (area of Fib/PA cross sectional area) × 100                            (4) 
A typical OCT image of a distal PA in a patient with IPAH is shown in Fig. 9. External and 
internal markers outline the area of fibrosis and the ratio between the fibrosis area and the 
external cross-sectional area estimates the percentage of wall fibrosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. In vivo OCT image of a distal pulmonary artery in a patient with IPAH. Calculation 
of the fibrosis of the arterial wall. 
The mean OCT %Fib was 23 ± 7, with an IVUSp of 33 ± 21% and an EP of 185 ± 107 mmHg.  
4.2 Correlation of local pulmonary fibrosis with steady and pulsatile afterload 
Histopathology of PAH is founded on structural modifications of the vascular wall of small 
PA characterized by thickening of all its layers. These changes include vascular wall 
proliferation, fibrosis and vessel obstruction (Sakao, Tatsumi & Voekel, 2010).  
In a model of chronic hypoxia PH, pulmonary vascular remodeling increases conduit PA 
stiffness. Vascular collagen accumulation is a major cause of extralobar PA stiffening in 
hypoxia PH. On the contrary, no significant change in elastin wall content has been 
observed (Ooi et al., 2010). In accordance with this, we found higher OCT %Fib in PA (1.5 to 
2 mm of diameter) of patients with IPAH with respect to control patients (23 ± 7 vs. 1.4 ± 
1.3%). Patients with a higher wall fibrosis showed higher steady (PVR increase) and 
pulsatile (Cp decrease) components of PA afterload. OCT %Fib was better correlated with 
A Area: 7.59mm
2
B Area: 5.88 mm2 
C AS%: B A = 22.5% 
Diameter: 1.37 mm
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capacitance (r = -0.47; p = 0.04), than with PVR (r = 0.44; p = 0.06) (Domingo et al., 2010). 
Although wall fibrosis is associated with an increase in EP, the absence of correlation 
between structural (OCT fibrosis) and functional (IVUSp; EP) wall remodeling, reveals the 
complex interaction between the different PA wall components in the remodeling process. 
The increased EP not only depends on the extent of wall fibrosis. Vasoconstriction, change in 
elastin wall content, transmural PA pressure and wall geometrical factors (thickness/radius 
ratio) also influence EP. Neither IVUS %Fib nor pulsatility was correlated with PA afterload.  
5. Conclusion 
PAH is a rare and severe condition characterized by vascular proliferation and remodeling 
of the small PA wall, resulting in a progressive increase in pulmonary vascular impedance 
and ultimately right ventricular failure and death. Both PA elastic modulus assessed by 
IVUS and wall percentage of fibrosis assessed by OCT correlated with the severity of PA 
dynamic afterload (global capacitance and resistance properties of the pulmonary arterial 
tree). Patients with a higher degree of remodeling had a worse clinical and hemodynamic 
profile. The severity of remodeling of elastic distal PA did not correlate with the acute 
response of mean PA pressure and/or PVRi to epoprostenol during the acute vasoreactivity 
test.  
We suggest the potential usefulness of IVUS and OCT as novel diagnostic tools for 
evaluation of PA wall functional and structural remodeling in patients with PAH group I, 
during acute vasoreactivity testing, along the disease process, and as a marker of treatment 
response, complementary to clinical and hemodynamic evaluation. It is possible that the 
current criteria for an acute positive pulmonary vasoreactivity test (decrease in  
Pm > 10 mmHg, reaching an absolute Pm < 40 mmHg with an unchanged or increased 
cardiac output) would not necessarily identify patients with lower vascular remodeling. 
This fact would explain the long-term clinical benefit of calcium blockers in only 50% of 
patients considered hemodynamic responders in the acute vasoreactivity testing. 
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